Correction: RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression.
1/5 보강
[This corrects the article DOI: 10.3389/fonc.2026.1741406.].
APA
Shi Y, Chen F, et al. (2026). Correction: RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression.. Frontiers in oncology, 16, 1814738. https://doi.org/10.3389/fonc.2026.1814738
MLA
Shi Y, et al.. "Correction: RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression.." Frontiers in oncology, vol. 16, 2026, pp. 1814738.
PMID
41858360
Abstract
[This corrects the article DOI: 10.3389/fonc.2026.1741406.].
🏷️ 키워드 / MeSH
같은 제1저자의 인용 많은 논문 (5)
- T cell-intrinsic PRR signaling in immunity and pathology.
- Blood-based biomarker discovery for early pregnancy loss using integrative multi-omics strategies.
- Global, regional, and national burden of lymphoma from 1990 to 2021: a comprehensive analysis based on the global burden of disease study 1990-2021.
- Prognostic significance of POD24 in primary central nervous system diffuse large B-cell lymphoma: a retrospective study.
- Comparison of Postoperative Adjuvant CTACE vs DEB-TACE Combined with Tislelizumab and Lenvatinib in BCLC Stage B/C Hepatocellular Carcinoma: A Propensity Score-Matched Analysis of Survival Outcomes.